Safety of STG320 Sublingual Tablets of House Dust Mite Allergen Extracts in Subjects with HDM-Associated Allergic Rhinitis: Results of a Pooled Analysis

Rationale Safety of house dust mite (HDM) sublingual tablets (STG320) for the treatment of HDM-associated allergic rhinitis (AR) with or without intermittent asthma has been assessed in seven DBPC clinical trials.

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 137; no. 2; p. AB403
Main Authors Demoly, Pascal M., Bergmann, Karl-Christian, Khairallah, Sandrine, Abiteboul, Kathy, Zeldin, Robert K.
Format Journal Article
LanguageEnglish
Published St. Louis Elsevier Inc 01.02.2016
Elsevier Limited
Subjects
Allergies
Allergy and Immunology
Drug dosages
Edema
Nose
Online AccessGet full text

Cover

More Information
Summary:Rationale Safety of house dust mite (HDM) sublingual tablets (STG320) for the treatment of HDM-associated allergic rhinitis (AR) with or without intermittent asthma has been assessed in seven DBPC clinical trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2015.12.1250